NCT05548231View on ClinicalTrials.gov

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions
OverweightObesity
Interventions
DRUG

LY3437943

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (2)

100034

Peking University First Hospital, Beijing

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY